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Abstract
Introduction: Macitentan is a novel dual endothelin-receptor antagonist with sustained receptor 
binding in clinical development for pulmonary arterial hypertension (PAH). Mecitentan has 
been accepted in US and Europe for PAH treatment. However there isn’t any data the use of 
macitentan in Indonesia yet. 
Aim:This review aimed to appraise the clinical evidences of macitentan for the treatment of 
pulmonary arterial hypertension. 
Method: We searched in major medical databases such as PubMed, MEDLINE, Clinical Key, 
Cochrane Library, and EMBASE. We limit our searchesonly for articles that can be obtained in 
full text, publishedin 10 years, and published in English. We used Jadad scaleto measure the 
quality of the evidences.
Results:We fi nd 3 trials that assesed effi cacy Mecitentan : SERAPHIN, MUSIC, and SERAPHIN 
Open Label. But only 1 trials with design randomized and double blind fashion that meet our 
criteria. The trial isSERAPHIN study. The SERAPHIN study compared macitentan 3mg and 
macitentan 10mg with placebo. The study have good quality in methodology (Jadad scale > 
3). The result of SERAPHIN study showed the benefi t of macitentan in reducing morbidity 
compared with placebo with relative risk reduction range from 34% to 41%, and also reduces  
mortality with relative risk reduction 48%. 
Conclusion:Our systematic review found that macitentan reduced morbidity and mortality 
among patient with PAH. In the future, the availability of macitentan in Indonesia will makes it 
one of options in PAH treatment.
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